Home \ General \ Why Mexidol®: history of creation, mechanism of action, safety and effect

Why Mexidol®: history of creation, mechanism of action, safety and effect

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Ivan Aleksandrovich Shchukin – PhD, Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics of the Leningrad Branch of the N.I. Pirogov Russian National Research Medical University

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Learn more in the video “Mexidol® – the standard of antioxidant neurocytoprotection.”

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Block of articles on this topic

Mexidol: a spectrum of pharmacological effects

Author:
VORONINA T.A.

Nii pharmacology named after V.V. Zakusov RAMS, Moscow

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. SHCHULKIN, A.A. FILIMONOVA
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University” of the Ministry of Health of the Russian Federation, Ryazan, Russia

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

Registered on ClinicalTrials

L.V. STAKHOVSKAYA¹, N.A. SHAMALOV¹, D.R. KHASANOVA², E.V. MELNIKOVA³, A.S. AGAFINA⁴, K.V. GOLIKOV⁵, E.I. BOGDANOV⁶, A.A. YAKUPOVA⁶, L.V. ROSHKOVSKA⁷, L.V. LUKINYKH⁸, T.M. LOKSHTANOVA⁹, I.E. Poverennova¹⁰, L.A. SCHEPANKEVICH¹¹

¹Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
²Interregional Clinical and Diagnostic Center, Kazan, Russia;
³St. Petersburg City Hospital No. 26, St. Petersburg, Russia;
⁴St. Petersburg City Hospital No. 40 of the Kurortny Administrative District, St. Petersburg, Russia;
⁵St. Petersburg City Multidisciplinary Hospital No. 2, St. Petersburg, Russia;
⁶Kazan State Medical University, Kazan, Russia;
⁷St. Petersburg Nikolaevskaya Hospital, St. Petersburg, Russia;
⁸Vsevolozhsk Clinical Interdistrict Hospital, Leningrad Region, Russia.
⁹MUBZ City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia;
¹⁰State Budgetary Healthcare Institution Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
¹¹Federal State Budgetary Scientific Institution Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2017, No. 3, ISSUE 2

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com